Navigation Links
GeoVax Labs, Inc. Announces Nine Month 2011 Financial Results
Date:11/10/2011

ATLANTA, Nov. 10, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm (the "Company") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results for the nine months ended September 30, 2011.

GeoVax reported a net loss of $375,852 ($0.02 per share) for the three months ended September 30, 2011, compared to $644,666 ($0.04 per share) for the same period in 2010. For the nine months ended September 30, 2011, the Company's net loss was $1,193,478 ($0.08 per share) as compared to $2,268,544 ($0.14 per share) for the same period in 2010.  Net losses were partially offset by revenues related to the Company's grant from the NIH in support of its HIV/AIDS vaccine development activities; such revenues were $1,297,006 and $3,943,041 for the three month and nine month periods of 2011, respectively, as compared to $1,163,288 and $4,239,017 for the three month and nine month periods of 2010, respectively.  As of September 30, 2011, the Company reported cash balances totaling $566,657, as compared to $1,079,087 at December 31, 2010.

GeoVax President and CEO Robert T. McNally, PhD, commented, "GeoVax continued to make solid progress during the third quarter of 2011. Our 299 participant Phase 2a clinical trial for the preventative version of our HIV/AIDS vaccine is fully enrolled and we expect patient inoculations to be completed during early 2012 with study analysis and completion during 2012. This trial is being conducted by the HIV Trials Network (HVTN), funded by the NIH. A preliminary unblinding of data from part 1 of this study showed elicitation of unexpectedly high response rates of neutralizing antibody for tier 2 isolates of HIV-1. The elicitation of neutralizing antibody for tier 2 viruses is an important result because tier 2 viruses represent viruses that undergo the most frequent transmission from an infected person to an uninf
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
2. GeoVax Labs, Inc. Information To Be Available Through Standard & Poors Market Access Program
3. GeoVax Presents Data at AIDS Vaccine 2008 Conference
4. GeoVaxs DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial
5. GeoVax Labs, Inc. Announces Third Quarter 2008 Financial Results and Provides Operational Update
6. GeoVax to Present at the BIO CEO & Investor Conference 2009
7. GeoVax to Webcast Its Presentation at the BIO CEO & Investor 2009 Conference
8. GeoVax Update Provided at the BIO CEO & Investor Conference 2009
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results
10. GeoVax Labs, Inc. Announces First Quarter Financial Results
11. GeoVax to Exhibit at the 2009 BIO International Convention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... PHILADELPHIA , Feb. 26, 2015  Spark Therapeutics (NASDAQ: ... its management team will participate in the Cowen and ... at 9:40 a.m., Eastern, at the Boston Marriott Copley ... a Spark Therapeutics presentation from the Cowen conference, please ... Events" section of the Spark Therapeutics website at ...
(Date:2/26/2015)... 26, 2015 On Wednesday, February 25, ... a nationwide Clostridium difficile (C. diff) awareness movement, lauded ... study by the Centers for Disease Control & Prevention ... half a million infections among Americans in a single ... , The study also estimates that 29,000 patients ...
(Date:2/26/2015)... 26, 2015 Phosphate Therapeutics, ... the first pivotal trial of PT20 in subjects ... disease (DD-CKD), has completed as the pre-specified number ... invented by leading UK-based scientists from the Medical ... is a novel phosphate binder that is based ...
(Date:2/25/2015)... 25, 2015 truBrain , creator ... in this week,s Power Pitch segment of CNBC,s  ... the company,s traction and growth strategy, as well ... funding site CircleUp. The segment highlights ... validated by neurotechnology, while also discussing its decision ...
Breaking Biology Technology:Spark Therapeutics to Participate in the 35th Annual Cowen and Company Health Care Conference 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 2Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 3Peggy Lillis Foundation Lauds CDC's New, More Comprehensive Study on the Burden of C. difficile Infections in the United States 4Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 2Phosphate Therapeutics Announces Completion of Subject Recruitment Into the PEACH Pivotal Phase 2 Study of its Novel Phosphate Binder (PT20) for the Treatment of Hyperphosphataemia 3CNBC's Power Lunch Features Neurotechnology Start-up truBrain 2
... researchers have found that the body,s innate ability to ... more effective and less costly artificial respirators. The new ... or paralysis currently necessary for some patients on mechanical ... adapt to recurring stimuli, is the focus of work ...
... Rice University chemists have discovered a way to load ... gold spheres. The result is a tiny ball, many times ... drug. , Paclitaxel, which is sold under the brand name ... works. , "Paclitaxel is one of the most effective anti-cancer ...
... new approach to discover life on Mars were successfully ... low-Earth orbit experiment to assess their survivability in the ... The new approach is based on technology similar to ... are embodied in the Life Marker Chip (LMC) experiment, ...
Cached Biology Technology:MIT: Leveraging learning for artificial respiration 2Taxol bristle ball: a wrench in the works for cancer 2Life on Mars 'pregnancy test' successfully launched 2
(Date:1/22/2015)... TORONTO , Jan. 13, 2015 /PRNewswire/ - Today, FindBiometrics, the ... announced the launch of its new website design. ... in its infancy", says Peter O,Neill , founder and ... ever, the industry needs involvement from the key players on ...
(Date:1/22/2015)... DETROIT , Jan. 13, 2015 Technology Showcase, Hall ... iris-based identity authentication solutions, today announced it will showcase its ... and developed by the Department of Energy,s Oak Ridge ... International Auto Show . EyeLock,s iris identity authentication technology is ...
(Date:1/22/2015)... N.C. , Jan. 16, 2015  A man-made form ... memory and other mental capabilities in adults with mild ... pilot study led by researchers at Wake Forest Baptist ... adults diagnosed with amnesic mild cognitive impairment (MCI) or ...
Breaking Biology News(10 mins):Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... has revealed that the extremely hot, dry and windy conditions ... ,horizontal convective rolls, -similar to streamers of wind flowing through ... study is the first of its kind to produce such ... provides insights for future fire management and warning systems. ...
... looking for information on the evolution and function ... Ravosa is your man. His integrative research ... the mammalian musculoskeletal system during development and across ... increasingly central role of the chewing complex in ...
... international research collaboration recently demonstrated progress in protecting cassava ... disease, in a confined field trial in Uganda using ... planted in November 2010 following approval by the National ... in November 2011 and results were published in the ...
Cached Biology News:Unusual weather events identified during the Black Saturday bushfires 2Notre Dame researcher is shedding light on how jaws evolve 2Researchers demonstrate control of devastating cassava virus in Africa 2
...
...
... Mouse polyclonal antibody raised against ... Immunogen: K6HF ... a.a) partial recombinant protein with ... Accession Number: NM_004693 ...
... role in the regulation of signaling pathways ... variants have been reported that affect both ... pathways. With Apoptosis and Cell Death ... profiling and at the same time detect ...
Biology Products: